Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CORT logo CORT
Upturn stock ratingUpturn stock rating
CORT logo

Corcept Therapeutics Incorporated (CORT)

Upturn stock ratingUpturn stock rating
$71.88
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/11/2025: CORT (4-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $138.25

1 Year Target Price $138.25

Analysts Price Target For last 52 week
$138.25 Target price
52w Low $31.46
Current$71.88
52w High $117.33

Analysis of Past Performance

Type Stock
Historic Profit 27.17%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/11/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.62B USD
Price to earnings Ratio 62.5
1Y Target Price 138.25
Price to earnings Ratio 62.5
1Y Target Price 138.25
Volume (30-day avg) 4
Beta 0.18
52 Weeks Range 31.46 - 117.33
Updated Date 07/13/2025
52 Weeks Range 31.46 - 117.33
Updated Date 07/13/2025
Dividends yield (FY) -
Basic EPS (TTM) 1.15

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 19.55%
Operating Margin (TTM) 2.17%

Management Effectiveness

Return on Assets (TTM) 9.18%
Return on Equity (TTM) 21.77%

Valuation

Trailing PE 62.5
Forward PE 56.18
Enterprise Value 7306564748
Price to Sales(TTM) 11.12
Enterprise Value 7306564748
Price to Sales(TTM) 11.12
Enterprise Value to Revenue 10.66
Enterprise Value to EBITDA 64.96
Shares Outstanding 106045000
Shares Floating 87673513
Shares Outstanding 106045000
Shares Floating 87673513
Percent Insiders 11.49
Percent Institutions 79.64

ai summary icon Upturn AI SWOT

Corcept Therapeutics Incorporated

stock logo

Company Overview

overview logo History and Background

Corcept Therapeutics Incorporated was founded in 1998 and focuses on the discovery, development, and commercialization of drugs to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol. Its initial focus was on Cushing's syndrome, a rare endocrine disorder.

business area logo Core Business Areas

  • Cushing's Syndrome: Development and commercialization of medications to treat Cushing's syndrome, a condition caused by prolonged exposure to high levels of cortisol.
  • Oncology: Research and development of cortisol modulation therapies for various cancers.
  • Metabolic Diseases: Exploring the potential of cortisol modulation in treating metabolic disorders.

leadership logo Leadership and Structure

Joseph K. Belanoff, M.D. serves as the Chief Executive Officer. The company has a standard corporate structure with departments focusing on research and development, commercial operations, finance, and legal.

Top Products and Market Share

overview logo Key Offerings

  • Korlym (mifepristone): Korlym is Corcept's primary product, used to treat Cushing's syndrome. While specific market share data fluctuates, Korlym holds a significant portion of the Cushing's syndrome medication market. Revenue from Korlym accounts for the majority of Corcept's revenue. Competitors are limited due to Korlym's unique mechanism of action, though alternative treatments for Cushing's exist, such as surgery, radiation, and other medications like Signifor (pasireotide) and Isturisa (osilodrostat).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and regulated. The focus is on developing and commercializing novel therapies for various diseases. Market trends include personalized medicine, advancements in biotechnology, and increasing regulatory scrutiny.

Positioning

Corcept is a specialty pharmaceutical company focused on cortisol modulation. Its competitive advantage lies in its expertise in this area and its established presence in the Cushing's syndrome market.

Total Addressable Market (TAM)

The global Cushing's syndrome market is estimated to be several hundred million USD. Corcept is well positioned, with potential to expand beyond Cushing's to other cortisol-related diseases. The TAM for oncology and metabolic disease applications is potentially much larger.

Upturn SWOT Analysis

Strengths

  • Established product in a niche market (Korlym)
  • Expertise in cortisol modulation
  • Strong intellectual property portfolio
  • Positive cash flow

Weaknesses

  • Reliance on a single product (Korlym)
  • Potential for generic competition
  • Lawsuits and patent challenges
  • Concentrated revenue source

Opportunities

  • Expansion into new indications (oncology, metabolic diseases)
  • Development of next-generation cortisol modulators
  • Partnerships and collaborations
  • Geographic expansion

Threats

  • Generic competition
  • Regulatory hurdles
  • Patent invalidation
  • Competition from other Cushing's treatments

Competitors and Market Share

competitor logo Key Competitors

  • Novartis (NVS)
  • Recordati Rare Diseases (No US Stock Symbol)
  • Millendo Therapeutics (MLNDQ) (Bankrupt)

Competitive Landscape

Corcept holds a dominant position in the Cushing's syndrome medication market with Korlym. Novartis competes with Signifor (pasireotide). The recent bankruptcy of Millendo Therapeutics and the acquisition of Isturisa by Recordati have altered the competitive landscape.

Growth Trajectory and Initiatives

Historical Growth: Corcept's growth has been primarily driven by increasing sales of Korlym and expanding its pipeline of cortisol modulation therapies.

Future Projections: Analyst estimates project continued revenue growth for Korlym and potential upside from its oncology and metabolic disease programs. However, projections are subject to regulatory approvals and clinical trial outcomes.

Recent Initiatives: Recent initiatives include advancing its oncology and metabolic disease pipeline, seeking regulatory approvals for new indications, and defending its intellectual property.

Summary

Corcept Therapeutics is a specialty pharmaceutical company with a strong position in the Cushing's syndrome market due to its drug, Korlym. The company's reliance on a single product represents a risk. Corcept is actively pursuing expansion into oncology and metabolic diseases to diversify its revenue streams, although any generic competition would pose a significant threat. A strong balance sheet and positive cash flow provide a solid foundation for future growth, but lawsuits related to patents do pose a risk to revenue and future potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Corcept Therapeutics Incorporated

Exchange NASDAQ
Headquaters Redwood City, CA, United States
IPO Launch date 2004-04-14
Co-Founder, President, CEO & Director Dr. Joseph K. Belanoff M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 500
Full time employees 500

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.